Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis

Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. News
May 8, 2025 - accessnewswire.com
Shareholders that lost money on West Pharmaceutical Services, Inc. (WST) should contact Levi & Korsinsky about pending Class Action - WST
May 8, 2025 - globenewswire.com
WST INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that West Pharmaceutical Services, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
May 8, 2025 - accessnewswire.com
Contact Levi & Korsinsky by July 7, 2025 Deadline to Join Class Action Against West Pharmaceutical Services, Inc. (WST)
May 8, 2025 - accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in West Pharmaceutical Services, Inc. of Class Action Lawsuit and Upcoming Deadlines - WST
West Pharmaceutical Services, Inc. Quantitative Score

About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
West Pharmaceutical Services, Inc. Earnings & Revenue
West Pharmaceutical Services, Inc. Financials
Table Compare
Compare WST metrics with: | |||
---|---|---|---|
Earnings & Growth | WST | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | WST | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | WST | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | WST | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
West Pharmaceutical Services, Inc. Income
West Pharmaceutical Services, Inc. Balance Sheet
West Pharmaceutical Services, Inc. Cash Flow
West Pharmaceutical Services, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Neutral |
Return on Equity | Strong Buy |
Return on Assets | Strong Buy |
Debt/Equity Ratio | Neutral |
Price/Earnings Ratio | Sell |
Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
West Pharmaceutical Services, Inc. Dividends
Yield (TTM) | Dividend (TTM) | |
---|---|---|
Infinity% | 0.8400 |
Payment Date | Dividend | Frequency |
---|---|---|
2025-08-06 | 0.21 | Quarterly |
2025-05-07 | 0.21 | Quarterly |
2025-02-11 | 0.21 | Quarterly |
2024-11-20 | 0.21 | Quarterly |
2024-08-07 | 0.2 | Quarterly |
West Pharmaceutical Services, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
West Pharmaceutical Services, Inc. Executives
Name | Role |
---|---|
Mr. Eric M. Green | Non-Independent Chair of the Board, President & Chief Executive Officer |
Mr. Bernard J. Birkett | Senior Vice President & Chief Financial Officer |
Ms. Kimberly Banks MacKay | Senior Vice President, General Counsel & Company Secretary |
Ms. Annette F. Favorite | Chief Human Resources Officer & Senior Vice President |
Ms. Kathy DePadua | Senior Vice President and Chief Quality & Regulatory Officer |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Mr. Eric M. Green | Non-Independent Chair of the Board, President & Chief Executive Officer | Male | 1970 | 1.59M |
Mr. Bernard J. Birkett | Senior Vice President & Chief Financial Officer | Male | 1969 | 887.33K |
Ms. Kimberly Banks MacKay | Senior Vice President, General Counsel & Company Secretary | Female | 1966 | 583.71K |
Ms. Annette F. Favorite | Chief Human Resources Officer & Senior Vice President | Female | 1965 | 545.78K |
Ms. Kathy DePadua | Senior Vice President and Chief Quality & Regulatory Officer | Female | -- |
West Pharmaceutical Services, Inc. Insider Trades
Date | 31 Mar |
Name | HAUGEN JANET BRUTSCHEA |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 56 |
Date | 18 Feb |
Name | Birkett Bernard |
Role | Sr VP, Chief Financial Officer |
Transaction | Acquired |
Type | M-Exempt |
Shares | 779.353 |
Date | 18 Feb |
Name | Birkett Bernard |
Role | Sr VP, Chief Financial Officer |
Transaction | Disposed |
Type | F-InKind |
Shares | 237.764 |
Date | 18 Feb |
Name | Birkett Bernard |
Role | Sr VP, Chief Financial Officer |
Transaction | Acquired |
Type | M-Exempt |
Shares | 124.977 |
Date | 18 Feb |
Name | Birkett Bernard |
Role | Sr VP, Chief Financial Officer |
Transaction | Disposed |
Type | F-InKind |
Shares | 35.606 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
31 Mar | HAUGEN JANET BRUTSCHEA | Director | Acquired | A-Award | 56 |
18 Feb | Birkett Bernard | Sr VP, Chief Financial Officer | Acquired | M-Exempt | 779.353 |
18 Feb | Birkett Bernard | Sr VP, Chief Financial Officer | Disposed | F-InKind | 237.764 |
18 Feb | Birkett Bernard | Sr VP, Chief Financial Officer | Acquired | M-Exempt | 124.977 |
18 Feb | Birkett Bernard | Sr VP, Chief Financial Officer | Disposed | F-InKind | 35.606 |